NCT03432299

Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma

Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma: Safety and Efficacy

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 19 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This is a single center prospective clinical trial with regard to efficacy and safety of radiofrequency ablation of papillary thyroid microcarcinoma.

Detailed description

For treatment of papillary thyroid microcarcinoma (PTMC), radiofrequency ablation (RFA) will be performed with the supine position and neck extended under ultrasonogrphic guidance. Before RFA, local anesthesia will be performed. RFA system including radiofrequency generator (VIVA RF system, STARmed, Goyang-si, Korea) and internally cooled electrode (star RF electrode, STARmed, Goyang-si, Korea) will be used. With regard to RFA procedure, moving shot technique and hydrodissection, if indicated, will be used. After RFA, follow-up will be performed using ultrasonography, serum thyroid function test, and questionnaire for quality of life by face-to-face interview at 2 months, 6, 12, 18, 24 months during the first 2 years after RFA, and yearly afterwards.

Conditions

• Papillary Thyroid Microcarcinoma
• Thyroid Cancer

Interventions

Type	Name	Description
PROCEDURE	RFA for PTMC	Radiofequency ablation for papillary thyroid microcarcinoma will be performed using the system including radiofrequency generator and internally cooled electrode.

Timeline

• Start date: 2018-04-16
• Primary completion: 2023-07-31
• Completion: 2023-12-31
• First posted: 2018-02-14
• Last updated: 2022-10-26

Locations

1 site across 1 country: South Korea